Rapport Therapeutics (RAPP) Gains from Sales and Divestitures (2024 - 2026)
Rapport Therapeutics (RAPP) reported Gains from Sales and Divestitures of $87574.0 for Q1 2026, up 64.83% year-over-year from $53130.0 in Q1 2025, and up 152.01% quarter-over-quarter from $34750.0 in Q4 2025.
Rapport Therapeutics (RAPP) Gains from Sales and Divestitures (2024 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has 3 years of Gains from Sales and Divestitures data on file, last reported at $87574.0 in Q1 2026.
- Gains from Sales and Divestitures for Q1 2026 came in at $87574.0, up 64.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $87574.0 (up 64.83% YoY), and the FY2025 annual result was $34750.0, down 94.3% from the prior year.
- Gains from Sales and Divestitures improved to $87574.0 in Q1 2026 per RAPP's latest filing, from $34750.0 in the prior quarter.
- Over five years, Gains from Sales and Divestitures peaked at $609402.0 in Q4 2024 and troughed at $34750.0 in Q4 2025.
- A 3-year average of $250906.2 and a median of $181940.5 in 2024 frame the typical range for Gains from Sales and Divestitures.
- On a YoY basis, Gains from Sales and Divestitures climbed as much as 154.95% in 2025 and fell as far as 94.3% in 2025.
- A 3-year view of Gains from Sales and Divestitures shows it stood at $609402.0 in 2024, then slumped by 94.3% to $34750.0 in 2025, then jumped by 152.01% to $87574.0 in 2026.
- Business Quant data shows RAPP's Gains from Sales and Divestitures at $87574.0 in Q1 2026, $34750.0 in Q4 2025, and $387569.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Rapport Therapeutics | 1.66 Bn | 1.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 87,574.00 |
| Mar 31, 2026 | 87,574.00 |
| Dec 31, 2025 | 34,750.00 |
| Dec 31, 2025 | 34,750.00 |
| Sep 30, 2025 | 387,569.00 |
| Sep 30, 2025 | 387,569.00 |
| Jun 30, 2025 | 261,364.00 |
| Jun 30, 2025 | 261,364.00 |
| Mar 31, 2025 | 53,130.00 |
| Mar 31, 2025 | 53,130.00 |
| Dec 31, 2024 | 609,402.00 |
| Dec 31, 2024 | 609,402.00 |
| Sep 30, 2024 | 470,944.00 |
| Sep 30, 2024 | 470,944.00 |
| Jun 30, 2024 | 102,517.00 |
| Jun 30, 2024 | 102,517.00 |